Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Net Cash Flow: 2015-2025

Historic Net Cash Flow for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to $37.2 million.

  • Intellia Therapeutics' Net Cash Flow rose 459.45% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 256.22%. This contributed to the annual value of -$37.6 million for FY2024, which is 87.27% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Net Cash Flow of $37.2 million as of Q3 2025, which was up 69.63% from $21.9 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Net Cash Flow registered a high of $385.7 million during Q4 2022, and its lowest value of -$229.4 million during Q1 2023.
  • For the 3-year period, Intellia Therapeutics' Net Cash Flow averaged around -$29.8 million, with its median value being -$10.4 million (2024).
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 1,629.85% in 2023, then surged by 459.45% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Net Cash Flow (Quarterly) stood at -$211.5 million in 2021, then spiked by 282.40% to $385.7 million in 2022, then crashed by 84.61% to $59.4 million in 2023, then grew by 15.70% to $68.7 million in 2024, then surged by 459.45% to $37.2 million in 2025.
  • Its Net Cash Flow stands at $37.2 million for Q3 2025, versus $21.9 million for Q2 2025 and -$54.6 million for Q1 2025.